Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU
As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast ...
The American Journal of Managed Care2h
FDA Approves First HER2-Ultralow Companion Diagnostic, Expanding Treatment Eligibility
Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...
Roche: FDA Approved Label Expansion for PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
MedPage Today3d
FDA Expands Enhertu Approval to HER2-Ultralow Breast Cancer
The FDA has specified use of the Ventana Pathway anti-HER2/neu (4B5) antibody assay. Additionally, the American Society for Clinical Pathology has guidelines for testing for HER2. Support for the ...
Taiho Oncology Presents Real-World Findings For LONSURF® At The ASCO Gastrointestinal Cancers Symposium
Real-world studies confirm that pairing LONSURF with bevacizumab increases efficacy in patients with metastatic colorectal cancer </b ...
Cure Today3d
FDA Approves Enhertu for HER2-Low and -Ultralow Breast Cancer
Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer after endocrine therapy progression, based on DESTINY-Breast06 trial results. Enhertu showed a 36% reduction in ...
Medscape3d
HER2 Overexpression/Amplification and Trastuzumab Treatment in Advanced Ovarian Cancer: A GINECO Phase II Study
Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...
The Boston Globe2d
On the night honoring her 2,000th point, Ava Orlando delivers in clutch for Notre Dame (Hingham) girls' basketball
HINGHAM — Before Tuesday’s game against Fontbonne, Notre Dame (Hingham) honored senior standout Ava Orlando with a sparkly gold ball that read: “2,000 points, Ava Orlando, No. 2, Notre Dame ...
WebMD6d
Cutting-Edge Treatments for HER2-Negative Breast Cancer
The doctor will test the receptors on your cancer. HER2 negative means your breast cancer tissue has little HER2 receptors or the gene that makes the HER2 receptor protein. This will rule out ...